The Great Peptide Cash Grab Has Begun
The FDA is considering reclassifying certain peptides to allow for legal compounding by pharmacies, potentially reversing a 2023 ban. Telehealth companies and compounding pharmacies are preparing for this shift, anticipating a significant new market for custom peptide treatments.
Why it matters
This decision could drastically expand access to experimental or custom-mixed medications, impacting both the telehealth industry and public health regulation.
Earlier this year, Robert F. Kennedy Jr. told the podcaster Joe Rogan that the government intended to loosen restrictions on peptide production. This week, it could finally happen: On July 23 and 24, the Food and Drug Administration will discuss whether to reclassify a group of peptides so that pharmacies can legally make custom mixes, a process known as compounding. The move would reverse a decision made in 2023 by the Biden Administration, which barred certain peptides from being compounded.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in